Three Studies Challenge the Cost-Effectiveness of GLP-1 Drugs vs. Bariatric Surgery

New research presented at the 2026 ASMBS annual meeting suggests bariatric surgery may be more cost-effective and produce better long-term health outcomes than GLP-1 medications across diverse patient populations.

Cost Comparison: Surgery vs. GLP-1 Drugs

A study of over 90,000 patients with obesity and type 2 diabetes found that surgical weight-loss options are substantially cheaper than GLP-1 drug therapy over a two-year period.

Using data from the STATinMED RWD Insights all-payor claims database (2017-2023), researchers conducted propensity score matching to compare:

• 4,931 GLP-1 patients to an equal number who underwent sleeve gastrectomy
• 4,272 GLP-1 patients to an equal number who underwent gastric bypass

Two-Year Total Costs

Total costs varied by insurance type and included the costs of treatments plus expenses from unresolved obesity-related diseases and complications.

"The assumption that drugs are more cost-effective due to lower upfront costs does not hold when considering durability, adherence, and payer structure."

— Michael A. Edwards, MD, bariatric surgeon at Mayo Clinic in Jacksonville

Impact on Chronic Kidney Disease

A separate study examined five-year outcomes of more than 8,900 patients with obesity and chronic kidney disease (CKD), comparing those who underwent sleeve gastrectomy or Roux-en-Y gastric bypass against those who did not have surgery. Data from 2010 to 2020 was sourced from the TriNetX Research Network electronic health record database.

Five-Year Outcomes for Surgery Patients

The results were striking across multiple measures:

• 50% lower risk of developing end-stage kidney disease (5.9% vs 11.9%)
• 60% reduction in the need for dialysis (4.1% vs 9%)
• More than double the rate of kidney transplants (4.6% vs 2.2%)
• Nearly 50% reduction in heart attack and stroke risk (15.5% vs 27.7%)
• Over 75% lower mortality rate (5% vs 16%)

"The findings suggest bariatric surgery alters the course of chronic kidney disease and should be considered earlier in the disease process."

— Jerry Dang, MD, PhD, FRCSC, FACS, FASMBS, Associate Professor of Surgery at Cleveland Clinic Lerner College of Medicine

Long-Term Effectiveness Across Socioeconomic Backgrounds

A long-running randomized clinical trial led by Dr. Mary Elizabeth Patti, an endocrinologist at Joslin Diabetes Center in Boston, compared bariatric surgery to medical and lifestyle interventions for type 2 diabetes.

The initial study assigned 355 participants to either medical therapy or one of three surgical approaches: gastric bypass, sleeve gastrectomy, or adjustable gastric lap banding. The study was conducted in Boston, Cleveland, Pittsburgh, and Seattle.

2024 Trial Outcomes

• Lower blood glucose levels
• Higher weight loss (28% versus 10%)
• Reduced use of diabetes medications
• Increased rates of diabetes remission
• Decreased risk factors for cardiovascular disease

How Social Background Affected Results

A secondary analysis, published in the Annals of Internal Medicine, investigated how social determinants of health affected outcomes. The analysis used data from 258 adults with type 2 diabetes, categorizing them by Area Deprivation Index based on ZIP codes. Participants' weight and hemoglobin A1c levels were tracked for seven to 12 years.

Key finding: Bariatric surgery yielded better results than medical therapy across all social backgrounds.

There was a trend toward improved outcomes from surgery for individuals in high deprivation areas, though this was not statistically significant.

Evolving Treatment Landscape

Over time, lap band surgery became less favored, and newer obesity drugs became more available. Some participants crossed over between medical and surgical treatments. By year 12:

• More than a third of the medical therapy group were receiving incretin-based therapies (such as GLP-1 agonists)
• Over a quarter of the surgical group were also on these medications

Background on Procedures

Metabolic and bariatric surgery, including gastric bypass and sleeve gastrectomy, is considered the most effective long-term treatment for severe obesity and related conditions. It can improve or resolve type 2 diabetes, heart disease, and high blood pressure, and leads to significant durable weight loss.

Safety profile: The safety of these surgeries is comparable to gallbladder surgery, appendectomy, and knee replacement.

The Big Picture

According to ASMBS, less than 1% of eligible patients undergo weight-loss surgery annually. In 2023, over 270,000 bariatric surgeries were performed in the U.S.

Meanwhile, CKD affects approximately 35.5 million Americans (1 in 7 adults) and is a leading cause of death in the US. Obesity, diabetes, and hypertension are the primary risk factors.